Clinical

A systematic review and meta-analysis presented at ACR Convergence 2022 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus (SLE).

Authors also found that the mortality rate of people with cutaneous lupus erythematosus (CLE) are generally similar to that of the general population.

This international study, from investigators in Germany and Austria, looked at the effect sacubitril/valsartan can have among patients who have heart failure with reduced ejection fraction (HFrEF) and the impact on their cardiac autonomic nervous system.

In addition to the drug approval, the FDA approved a companion diagnostic to be used to identify patients who are eligible to receive the treatment.

Key opinion leaders provide their final thoughts on treatment management for patients with MDS.

The child living with spinal muscular atrophy (SMA) type 2 had less fatigue and improved functional scores as time went on.

These second-generation basal insulin analogs, Gla-300 and IDeg-100, also had similar safety profiles, investigators found.

Despite knowledge of chronic rhinosinusitis and inflammatory bowel diseases (IBDs) sharing dysfunctional mucosa, little is known of potential associations between sinusitis and IBD, which prompted this new study.

This new study shows how using electronic health record (EHR) data can objectively quantify patient treatment burden among individuals who have multiple myeloma (MM) compared with patient-reported outcomes, which can be subject to recall bias.

Laura Bobolts, PharmD, BCOP, discusses key cost drivers impacting treatments for upper GI and esophageal cancers.

Laura Bobolts, PharmD, BCOP, and James M. Cleary, MD, PhD, explore the evolution of treatment for patients with upper GI and esophageal cancer, including first- and second-line treatment strategies for gastroesophageal cancer.

Panelists provide their key considerations when determining appropriate treatment options for patients with major depressive disorder.

Key opinion leaders discuss the importance of early effective treatment for patients with MDD.

The disease groups that make up the OneOncology clinical pathways program cover 90% of patients with cancer and develop best practices for treating cancer in the majority of patients, said Edward “Ted” Arrowsmith, MD, MPH, managing partner and director of research, East Tennessee Division, Tennessee Oncology.

With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.

The study highlights a need for further research into potential contributors, including the possibility that sicker patients may receive more prompt treatment.

The OneOncology Annual Conference is being held November 11-13 in Nashville, Tennessee, and brings together practice leaders, physicians, and advanced practice providers to discuss the business of oncology and scientific advancements, explained Davey Daniel, MD, chief medical officer of OneOncology.

Over the course of voxelotor treatment, hemoglobin levels and hemolysis markers improved, with results sustained over the treatment period.

Dr Siefker-Radtke provides her closing thoughts on her takeaways from ESMO 2022, including a study focusing on penpulimab plus anlotinib.

Representatives across 12 disease groups make up a council that sets clinical recommendations for oncology care and those decisions are being pushed out in the electronic medical record for decision support at the point of care, said Jeffrey Patton, MD, CEO, OneOncology, and executive chairman of the board, Tennessee Oncology. Patton will lead off OneOncology's Physician Leadership Conference, which runs November 11-13 in Nashville.

Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer.

Genetic factors previously known to predispose people to hyperopia were not risk factors for clinically significant depression in the study.

Dr Siefker-Radtke shares takeaways from the SOGUG-AUREA study and its influence on treatment for patients with urothelial cancer.

Mobile health (mHealth) and a patient activation program could serve as a model for improving health outcomes for patients in outpatient clinical settings by decreasing atherosclerotic cardiovascular disease risk score.

The hesitation to prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) to patients with hemophilia is not supported by current research, based on a recently published review, but the available studies had significant limitations.